Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Practice Point
  • Published:

Fluvastatin for reduction of cardiovascular risk in patients with moderate to severe renal insufficiency

Nature Clinical Practice Nephrology volume 3, pages 530–531 (2007)Cite this article

boxed-textHoldaas H et al. (2007) The effect of fluvastatin on cardiac outcomes in patients with moderate to severe renal insufficiency: a pooled analysis of double-blind, randomized trials. Int J Cardiol 117: 64–74

Background

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

References

  1. Baigent C et al. (2000) Premature cardiovascular disease in chronic renal failure. Lancet 356: 147–152

    Article  CAS  Google Scholar 

  2. Serruys PW et al. (2001) The Lescol® Intervention Prevention Study (LIPS): a double-blind, placebo-controlled, randomized trial of the long-term effects of fluvastatin after successful transcatheter therapy in patients with coronary heart disease. Int J Cardiovasc Intervent 4: 165–172

    Article  Google Scholar 

  3. Holdaas H et al. (2003) Effect of fluvastatin on cardiac outcomes in renal transplant recipients: a multicentre, randomised, placebo-controlled trial. Lancet 361: 2024–2031

    Article  CAS  Google Scholar 

  4. Wanner C et al. (2005) Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis. N Engl J Med 353: 238–248

    Article  CAS  Google Scholar 

  5. Landray M et al. (2006) The second United Kingdom Heart and Renal Protection (UK-HARP-II) Study: a randomized controlled study of the biochemical safety and efficacy of adding ezetimibe to simvastatin as initial therapy among patients with CKD. Am J Kidney Dis 47: 385–395

    Article  CAS  Google Scholar 

Download references

Acknowledgements

The synopsis was written by Chloë Harman, Associate Editor, Nature Clinical Practice.

Author information

Authors and Affiliations

  1. R Haynes is a Clinical Research Fellow at the Clinical Trial Service Unit of the University of Oxford and J Armitage is a Reader in Clinical Epidemiology and Honorary Consultant in Public Health Medicine at the University of Oxford, Oxford, UK.,

    Richard Haynes & Jane Armitage

Authors
  1. Richard Haynes
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Jane Armitage
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Richard Haynes.

Ethics declarations

Competing interests

J Armitage is on the Steering Committee of the Study of Heart and Renal Protection (SHARP), which is sponsored by Merck & Co. R Haynes declared no competing interests.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Haynes, R., Armitage, J. Fluvastatin for reduction of cardiovascular risk in patients with moderate to severe renal insufficiency. Nat Rev Nephrol 3, 530–531 (2007). https://doi.org/10.1038/ncpneph0583

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/ncpneph0583

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing